Considering that these side effects are believed to be a class effect due to the inhibition of COX-2 and the resulting imbalance of prostanoids [8,87,88], it is tempting to speculate that the clinical use of a celecoxib analog such as DMC, which lacks COX-2 inhibitory function but maintains anti-tumor potency, perhaps might avoid many of these unwanted side effects – and possibly could be used at even higher dosages than celecoxib for certain anti-tumor purposes. This evidence concerns the gene PTGS2 and neoplasm.